Table 1. Clinical trials currently available with immune checkpoint inhibitors in HCC.

ClinicalTrials.gov identifier	Agent(s)	Target	Locoregional therapy	Study design	First or second line
NCT02795429	PDR001/INC280	PD-1/cMET	None	Ib/II	Second line
NCT02702401	Pembrolizumab	PD-1	None	III	Second line
NCT02702414	Pembrolizumab	PD-1	None	II	Second line
NCT02856425	Pembrolizumab/Nintedanib	PD-1/VEGFR, PDGFR, FGFR	None	I	Second line
NCT02821754	Tremelimumab/Durvalumab	CTLA-4/PD-L1	RFA/TACE/Cryoablation	Pilot	Second line
NCT02988440	PDR001/Sorafenib	PD-1/Raf, VEGFR, PDGFR	None	Ib	First line
NCT02989922	SHR-1210	PD-1	None	II/III	Second line
NCT02576509	Nivolumab/Sorafenib	PD-1/Raf, VEGFR, PDGFR	None	III	First line
NCT03033446	Nivolumab	PD-1	Radioembolization	II	First line
NCT02859324	CC-122/Nivolumab	CRBN/PD-1	None	I/II	Second line
NCT02423343	Galunisertib/Nivolumab	TGF-β1/PD-1	None	Ib/II	Second line
NCT01658878	Nivolumab/Ipilimumab	PD-1/CTLA-4	None	I/II	First and second line
NCT02837029	Nivolumab	PD-1	Yttrium microspheres	I/Ib	First and second line
NCT01853618	Tremelimumab	CTLA-4	RFA/TACE/SBRT/Cryoablation	Pilot	Second line

HCC, hepatocellular carcinoma; PD-1, programmed death 1; CTLA-4, cytotoxic T lymphocyte associated protein 4; VEGF, vascular endothelial growth factor; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; TGF-β, transforming growth factor β; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; SBRT, stereotactic body radiation therapy.